New drug could reduce Blood-Letting for polycythemia vera patients

NCT ID NCT07429266

Recruiting now Disease control Sponsor: Ono Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 4 times

Summary

This phase 3 trial tests whether adding the drug sapablursen to standard treatment helps people with polycythemia vera, a blood disorder causing too many red blood cells. About 250 participants who currently need regular blood removal (phlebotomy) will receive either sapablursen or a placebo for up to 156 weeks. The main goal is to see if the drug reduces the need for phlebotomy and improves fatigue.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sapablursen (a drug injected under the skin)
What this could lead to: If it works, this could offer a new treatment option to help control polycythemia vera and reduce the need for regular blood removal (phlebotomy).
What could go wrong: This is still an experimental drug, and its safety and effectiveness are not yet proven. Even if successful, it would manage the disease rather than cure it, and long-term risks are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POLYCYTHEMIA VERA

Contacts and locations

Locations

Florida Clinical Trials Group
RECRUITING

Plantation, Florida, 33322, United States
Florida Clinical Trials Group
RECRUITING

Tamarac, Florida, 33321, United States
Gabrail Cancer Center Research
RECRUITING

Canton, Ohio, 44718, United States
Montefiore Medical Center
RECRUITING

The Bronx, New York, 10461, United States
Regis Clinical Research LLC.
RECRUITING

Miami, Florida, 33126, United States
The Center for Cancer & Blood Disorders
RECRUITING

Bethesda, Maryland, 20817, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.